orforglipron vs tirzepatide

orforglipron (S-tier) vs tirzepatide (S-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

orforglipron · tier S

foundayo. the first non-peptide small-molecule oral GLP-1 receptor agonist. a once-daily pill, no injection, FDA-approved april 2026 for chronic weight management.

a small molecule, not a peptide. the first non-peptide oral GLP-1 receptor agonist to reach FDA approval. eli lilly's once-daily pill, sold as foundayo.

~12.4% ATTAIN-1 wt loss · half-life supports once-daily oral dosing per the FDA-approved label; small-molecule oral absorption without the food/water restrictions of oral peptide GLP-1s · weight loss

tirzepatide · tier S

A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.

The obesity record is strong, but every outcome must stay attached to its trial population and product label.

20.9% SURMOUNT-1 mean change at 15 mg · half-life ~5 days · weight loss

at a glance

• orforglipron: tier S · ~12.4% ATTAIN-1 wt loss
• tirzepatide: tier S · 20.9% SURMOUNT-1 mean change at 15 mg

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.